Special Issue

Mechanism of Carbapenem Resistance in *Enterobacteriaceae*, *Acinetobacter* and *Pseudomonas aeruginosa*

Message from the Guest Editor

Infections caused by carbapenem-resistant Gram-negative pathogens, i.e., carbapenem-resistant *Enterobacteriaceae* (CRE), carbapenem-resistant *Acinetobacter baumannii* (CRAB), and MDR *Pseudomonas aeruginosa* are listed by the World Health Organization as pathogens of critical priority. Infections caused by such pathogens are difficult to treat, even if we consider the beta-lactam/beta lactamase inhibitor (BL/BLI) drugs and cefiderocol, which were recently introduced into medical practice. Manuscripts are invited concerning the following areas of interest:

- In vitro diagnostic tools for the phenotypic detection of carbapenemase enzymes and carbapenem resistance in *Enterobacteriaceae*, *Acinetobacter spp.*, and *Pseudomonas aeruginosa*;
- Molecular epidemiology of CRE, CRAB, and carbapenem-resistant *Pseudomonas aeruginosa*;
- Evaluation of the treatment efficacy of the new beta-lactam/beta lactamase inhibitors or cefiderocol in infections caused by CRE, CRAb and MDR *aeruginosa* in relation to their resistance mechanisms.

Guest Editor

Dr. Ágnes Pál-Sonnevend

Department of Medical Microbiology and Immunology, University of Pécs Medical School, 7624 Pecs, Hungary

Deadline for manuscript submissions

31 October 2025

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/115735

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI